GLP-1 drugs for heart health Trulicity (dulaglutide) was approved in 2020 for individuals with type 2 diabetes, with or without a history of heart disease, to help reduce the risk of serious cardiovascular events, like heart attacks
Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, et al
The bright and the dark sides of L-carnitine supplementation: A systematic review
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Broader health protection: Improvements in liver markers may reduce the risk of metabolic dysfunction and MASLD/MASH (fatty liver progression)
Furthermore, some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs (94, 95)